title: Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor.
abstract: Preclinical and clinical studies consistently demonstrate the antitumor activity of the various monoclonal antibodies (mAbs) that block ligand binding to the extracellular domain of the epidermal growth factor receptor (EGFR). However, the objective antitumor activities of these agents are disproportionately lower than would be expected based on the high rates of expression, overexpression, and aberrations of EGFR in human malignancies, particularly carcinomas. Several technologic and clinical approaches are being explored to optimize the potency of these antibodies, such as humanization of the murine parent molecules, and conjugation and widening of the specificity of the mAb. Also, combined therapy with the different types of EGFR-interacting or other targeted agents may lead to a heightened potential. This review highlights the results of current approaches for improvement of the therapeutic indices of these agents.
authors.affiliation: Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, 4th Floor, Zeller Building, San Antonio, TX 78229, USA.
authors.forename: Emiliano
authors.initials: E
authors.lastname: Calvo
authors.forename: Eric K
authors.initials: EK
authors.lastname: Rowinsky
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015195:Drug Design; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D066246:ErbB Receptors
references.citation: Cancer Immunol Immunother. 2003 May;52(5):342-6
references.pmid: 12700950
references.citation: J Nucl Med. 2002 May;43(5):693-713
references.pmid: 11994535
references.citation: Cancer Treat Rev. 2004 May;30(3):255-68
references.pmid: 15059649
references.citation: Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5
references.pmid: 9435876
references.citation: Hematol Oncol Clin North Am. 2002 Oct;16(5):1041-63
references.pmid: 12512382
references.citation: Clin Cancer Res. 2004 Oct 1;10(19):6487-501
references.pmid: 15475436
references.citation: J Natl Cancer Inst. 2004 Jul 7;96(13):980-1
references.pmid: 15240773
references.citation: J Immunol Methods. 1999 Dec 10;231(1-2):11-23
references.pmid: 10648924
references.citation: Br J Cancer. 1995 Oct;72(4):928-33
references.pmid: 7547242
references.citation: Curr Oncol Rep. 2005 Mar;7(2):96-103
references.pmid: 15717942
references.citation: Cancer Res. 1993 Sep 15;53(18):4322-8
references.pmid: 8364927
references.citation: Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10842-7
references.pmid: 9724792
references.citation: J Pharm Sci. 2004 Nov;93(11):2645-68
references.pmid: 15389672
references.citation: Nat Med. 2000 Apr;6(4):443-6
references.pmid: 10742152
references.citation: Cancer Res. 1995 Dec 1;55(23):5536-9
references.pmid: 7585629
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1201-8
references.pmid: 14993230
references.citation: Cancer Immunol Immunother. 2000 Nov;49(9):493-503
references.pmid: 11092616
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3003-15
references.pmid: 15210739
references.citation: J Clin Oncol. 2004 Jan 1;22(1):175-84
references.pmid: 14701780
references.citation: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references.pmid: 11252954
references.citation: Mol Cell. 1998 Nov;2(5):581-91
references.pmid: 9844631
references.citation: Cancer Cell. 2003 Mar;3(3):207-12
references.pmid: 12676579
references.citation: Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22
references.pmid: 11597400
references.citation: Genomics. 2001 Jan 1;71(1):1-20
references.pmid: 11161793
references.citation: Ann Oncol. 1999 Jun;10(6):655-61
references.pmid: 10442187
references.citation: Clin Cancer Res. 1997 Nov;3(11):2099-106
references.pmid: 9815602
references.citation: J Immunother. 2003 Mar-Apr;26(2):139-48
references.pmid: 12616105
references.citation: J Med Chem. 2002 Dec 19;45(26):5620-3
references.pmid: 12477344
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Clin Exp Metastasis. 2000;18(2):155-61
references.pmid: 11235991
references.citation: Cancer Res. 1993 Sep 1;53(17):4026-34
references.pmid: 7689421
references.citation: Cancer Res. 2004 Apr 1;64(7):2343-6
references.pmid: 15059883
references.citation: Int Immunol. 2001 Dec;13(12):1551-9
references.pmid: 11717196
references.citation: J Clin Oncol. 2000 Feb;18(4):904-14
references.pmid: 10673534
references.citation: Clin Cancer Res. 2004 Jul 1;10(13):4363-8
references.pmid: 15240523
references.citation: Cancer Res. 2001 Jul 15;61(14):5349-54
references.pmid: 11454673
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S122-6
references.pmid: 14508089
references.citation: Cancer Res. 2001 Feb 1;61(3):1045-9
references.pmid: 11221831
references.citation: Nat Biotechnol. 2000 Feb;18(2):194-8
references.pmid: 10657127